Cell Culture Market

The Cell Culture Market is valued at USD 23.6 Bn in 2026 and is projected to reach USD 51.9 Bn, growing at a CAGR of 12% by 2033.

Growing Awareness about Cell & Tissue Culture Techniques to Fuel Cell Culture Market Growth

Cell culture is an important technique in both cellular and molecular biology given that it provides the best platform for studying the normal physiology and biochemistry of cells. Increasing awareness of the cell culture technique, as well as enhanced use of this technique for producing biological compounds such as recombinant proteins or antibodies, is propelling the cell culture market forward. Cell culture techniques are increasingly being used by researchers and biopharmaceutical companies to develop vaccines for a wide range of diseases, including polio, smallpox, hepatitis, rubella, and chickenpox. The rising prevalence of chronic and infectious diseases globally, combined with the rising demand for vaccines, will drive the cell culture market during the forecast period.

According to the World Health Organization (WHO), chronic diseases caused 41 million deaths worldwide in 2021. Cardiovascular disease is the most common chronic disease, killing 17.9 million people every year, followed by cancer (9.3 million), respiratory disorders (4.1 million), and diabetes (1.5 million). As a result of the high number of deaths caused by chronic diseases, market leaders are now being pushed to improve and innovate biologics products. The rising incidence of infectious diseases, as well as the growing threat of pandemics, are expected to drive global vaccine demand. Cell culture has become an important part of vaccine production in the pharmaceutical industry. Flu vaccines based on cells have also been approved for use in the US and many European countries. Increasing awareness of the benefits of cell culture-based vaccines, as well as the regulatory approval of several cell culture-based vaccines globally, are the major factors enhancing the growth of the cell culture market.

Moreover, increased R&D investments and the establishment of new manufacturing sites for biopharmaceutical mass production will create growth opportunities in the global cell culture market. For instance, Fujifilm Corporation invested more than 200 billion yen in January 2021 to establish a new large-scale cell culture production plant for biopharmaceuticals in the United States. This will support the company's biopharmaceutical contract development and manufacturing business to grow faster.

Drug Screening & Development Segment Application to Lead the Cell Culture Market

Drug screening & development is expected to be the fastest-growing segment of the cell culture market over the forecast period. The increasing prevalence of various chronic diseases, rising public awareness of biopharmaceuticals, and a surge in biopharmaceutical production and consumption globally are all contributing to the segment's growth. The drug screening and development process is at its peak in the biotechnology industry as a result of the COVID-19 outbreak. Several companies and research organisations are working to develop coronavirus drugs/vaccines. For instance, Entos Pharmaceuticals, Roivant Sciences, Altimmune, Biopharma, and others are developing drugs to treat contagious coronavirus infection, which is expected to drive segment growth. Furthermore, the rapid expansion of the biopharmaceutical contract manufacturing market in developed and developing markets will support the growth of this segment.

Increased Healthcare Expenditure and Presence of Leading Market Players to Drive Growth of North American Cell Culture Market

North America continues to lead the cell culture market and is expected to continue in this manner over the forecast period. This is primarily due to the growing demand for personalized medicine and the presence of key market players. Besides, other factors such as an increase in health expenditure fuel the growth of the cell culture market in North America. The US has become the global centre for drug research and development over the years. Government and non-government organisations spend billions of dollars each year on research and development. For instance, the National Institutes of Health (NIH) alone spends approximately USD 41.7 billion on medical research for the American people every year.

Technological advancements in cell culture instruments and equipment have also contributed to significant growth in this region. The U.S. healthcare and life science industries are early adopters of cell culture techniques, which has resulted in the country's large market share. The ongoing research and expansion of the country's biopharmaceutical sector are one of the driving factors driving the cell culture market in the U.S. A large number of biotherapeutics are currently under clinical development and are produced using a variety of cell lines, including mammalian and transgenic. As a result of this growth, there is a greater demand for and development of creative solutions to address the rising needs of local customers. For instance, in January 2022, Mammoth Biosciences announced a collaboration deal with the German corporation Bayer to develop in vivo gene editing therapeutics using Mammoth's CRISPR system. Such collaborative campaigns are propelling the market.

Moreover, the rapid growth of the cell culture market in the Asia Pacific can be ascribed to the rising biopharmaceutical research, strong government support, and expansion of biopharmaceutical manufacturers. Low manufacturing costs in China and India have increased production capacity, drawing pharmaceutical and biotech companies to the region. The cell culture market in India is being driven by technological advancements, the development of regenerative therapies, and the rising incidence of hereditary and chronic disorders. In addition, government initiatives to keep up with the industry's growing drug development trends play a significant role in driving the market. For instance, in January 2022, the Union Health Ministry of India amended the New Drugs & Clinical Trials Act to include cell culture-derived products in the new definition of new drugs with stem cell products. Government initiatives like these are expected to boost the market.

Companies in the market are launching new products alongside initiation collaborations, alliances, and partnership agreements. For instance, in October 2021, Thermo Fisher Scientific Inc. (US) introduced the Gibco Cell Therapy Systems (CTS) NK-Xpander Medium, which enables the large-scale growth and culture of functional natural killer (NK) cells with or without the use of feeder cells. On the other hand, in July 2021, Sartorius AG announced the acquisition of cell culture specialist Xell AG to expand the company's current media product for manufacturing viral vectors as well as in the area of media analytics.

Few of the players in the Cell Culture market include:

• Thermo Fisher Scientific
• Merck KGaA (MilliporeSigma)
• Danaher Corporation (including Cytiva & Pall)
• GE Healthcare Life Sciences (Cytiva)
• Corning Incorporated
• Lonza Group Ltd.
• BD (Becton, Dickinson and Company)
• Sigma-Aldrich (part of Merck)
• Bio-Rad Laboratories, Inc.
• Takara Bio Inc.
• Agilent Technologies, Inc.
• Promega Corporation
• PerkinElmer, Inc.
• Eppendorf AG
• ATCC 

Global Cell Culture Market is Segmented as Below:

By Product
• Consumables
• Equipment

By Application
• Biopharmaceutical Production
• Diagnostics
• Tissue Engineering & Regenerative Medicine
• Drug Screening & Development
• Other Applications

By End User
• Pharmaceutical & Biotechnology Companies
• Hospitals & Diagnostic Laboratories
• Research & Academic Institutes
• Other

By Region
• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa